31 results about "Chlidanthine" patented technology

The present invention relates to derivatives of berberine dimer analog JJA-D0 or pharmaceutically acceptable salts, preparation methods and uses thereof. The compound has the structure of general formula (I). The present invention introduces hydrocarbon groups, aryl groups, heteroaryl groups, alkoxycarbonyl groups, acyl groups, sulfonate groups, antioxidant groups such as lipoic acid groups, H 2 S donor groups such as cysteinyl, NO donor groups such as nitrate groups, etc., synthesized and disclosed a series of compounds with new structures. These compounds can inhibit NADPH oxidase, and have a better anti-oxidation and anti-inflammatory dual pharmacological mechanism than berberine. Some of these compounds can also provide NO, H 2 The donor group of S can further enhance the pharmacological activity, and it is a new class of multifunctional compound. The disclosed JJA-D0 derivatives can be used to prevent or treat diseases related to NADPH oxidase, diseases related to free radicals, diseases related to inflammation, diseases related to NO, diseases related to H 2 Preparation of health products or medicines for S-related diseases.

The invention relates to a berberine anti-tumor platinum (II) complex, its synthesis method and the application of the complex in the preparation of anti-tumor drugs. The synthesis method of the berberine anti-tumor platinum (II) complex comprises the following steps: (1) dissolving the brominated berberine derivative, potassium halide and lutidine amine in a solvent, and reacting at 90° C. to obtain B ‑TFA ligand; (2) the B‑TFA ligand prepared in step (1) and dichlorobis(dimethylsulfoxide) platinum (II) are dissolved in acetonitrile solution, and carry out coordination reaction 4~6 Hours, the product was washed and dried to obtain. The present invention uses the brominated berberine derivative B-TFA as the active ligand for the first time to synthesize its platinum complex, which exhibits superior anti-tumor activity and targeting in vivo and in vitro, has potential medicinal value, and is expected to be used in various Preparation of antineoplastic drugs. The structural formula of the berberine anti-tumor platinum (II) complex is as follows:

The invention relates to medicine and a preparation technology thereof, namely heat clearing and hematostatic Mongolian medicine and preparation technology thereof. The Mongolian medicine is characterized by being prepared from the following active ingredients in parts by weight: 1 to 2 parts of gardenoside, 1 to 2 parts of rutin, 1 to 2 parts of carthamin, 1 to 2 parts of beta-sitosterol, 1 to 2parts of rheum emodin, 1 to 2 parts of glycyrrhizic acid, 1 to 2 parts of kutkin, 1 to 2 parts of rubican, 1 to 2 parts of alkannin, 1 to 2 parts of shellac resin, 3 to 5 parts of calcium carbonate, 3to 5 parts of calcium phosphate, 3 to 5 parts of amino acid, 2 to 3 parts of cholic acid and 2 to 3 parts of calculus bovis. The Mongolian medicine has the beneficial effects of heat clearing, bloodcooling and hematostatic effects, obvious curative effects on hemorrhage syndromes of hematemesis, hemafecia, menorrhagia, traumatic bleeding, liver diseases and the like, low toxic and side effect, wide suitable crowd range, convenience in taking, convenience in digestion and absorption and quick effect; thus, the Mongolian medicine hopefully becomes typical medicine for treating lung diseases.

The invention discloses a method for purifying berberine or its salt, comprising: converting a raw material mainly containing berberine or berberine salt I into an acetone adduct of berberine, and then converting the acetone adduct of berberine into Berberine salt II to obtain the product berberine salt II or berberine. The invention also discloses an acetone adduct crystal form of berberine. Adopt purification method of the present invention, berberine acetone adduct is converted into berberine acetone adduct by raw material containing berberine or berberine salt, then berberine acetone adduct is converted into final product berberine or its salt, can obtain high The pure berberine or its salt has a total impurity content of less than 0.2 percent and a single impurity content of less than 0.1 percent, which ensures the safety of the drug.

The invention discloses a drug co-crystal of dihydromyricetin-berberine hydrochloride, which belongs to the technical field of drug crystallization. The present invention combines dihydromyricetin and berberine hydrochloride through intermolecular hydrogen bonding to form the dihydromyricetin-berberine hydrochloride drug eutectic. The preparation method of the invention is simple and easy, and the cost is low. The prepared dihydromyricetin-berberine hydrochloride drug eutectic structure is clear, without hygroscopicity, and the dissolution rate of dihydromyricetin and berberine hydrochloride in water is similar, and can be dissolved simultaneously, showing a synergistically enhanced effect on specific tumor cells. inhibition.

The present invention relates to a cooling agent, and medicated ice-bag with said cooling agent and its application method. The cooling agent of said medicated ice-bag is a compound liquor whose composition contains (by volume ratio) 20% of absolute ethyl alcohol, 10% of glycerol, 20% of calcium chloride, 10% of sodium chloride, 1% of berberine and 39% of water. It does not ice at 55 deg.C below zero, and it is made into a flocculent material, its thermal eapacity is 2 calorie / g / deg.C, and it can absorb lots of heat quantity.

The invention discloses fenofibric acid salts of berberine and analogues thereof, a crystal form, a preparation method and applications thereof, wherein the fenofibric acid salt comprises fenofibric acid serving as an anion and berberine or a berberine analogue serving as a cation. According to the invention, the fenofibric acid salt of berberine or analogue thereof can be used for removing unnecessary cations from commercially available medicines, ie., choline cations in choline fenofibrate and / or chlorine ions in berberine hydrochloride, so that a certain side effect, including gastrointestinal irritation due to instability property of choline as an anion and high acidity of berberine hydrochloride, caused by the two pairing ions can be reduced.